Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash from Financing Activities data on file, last reported at $17.2 million in Q3 2025.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $17.2 million in Q3 2025; TTM through Sep 2025 was $78.7 million, a 7551.46% increase from a year earlier, with the FY2024 full-year figure at $56.0 million, down 52.54% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $17.2 million, up from $7.4 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for EDIT reached as high as $261.5 million in Q1 2021 and fell as low as -$1.4 million in Q1 2025.
• Historically, Cash from Financing Activities has averaged $30.0 million across 5 years, with a median of $838000.0 in 2021.
• Across the five-year window, Cash from Financing Activities soared 31923.16% in 2023 and sank 848.44% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $1.1 million in 2021, then tumbled by 41.44% to $619000.0 in 2022, then dropped by 16.96% to $514000.0 in 2023, then jumped by 10700.19% to $55.5 million in 2024, then slumped by 69.07% to $17.2 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $17.2 million in Q3 2025, $7.4 million in Q2 2025, and -$1.4 million in Q1 2025.